Trodelvy recommended in England for metastatic triple negative breast cancer

pharmafile | July 14, 2022 | News story | Business Services  

Gilead Sciences has announced the NICE recommendation of Trodelvy (sacituzumab govitecan) for use on the NHS in England, as an option for treating unresectable triple-negative locally advanced or metastatic breast cancer in adults.

The treatment has been recommended within its marketing authorisation for adults after two or more systemic therapies at, at least one of which was for advanced disease.

Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer and there is a limited number of therapeutic options available, particularly for those whose disease has metastasised.

Professor Christopher Twelves, Honorary Consultant in Oncology at Leeds Teaching Hospitals said: “Treating women with triple-negative breast cancer has been notoriously challenging and, once the cancer has spread, there have been few treatment options that meaningfully impact on survival. Today’s decision changes that. We now have the option to use a potent, targeted therapy that has definitively shown potential to increase survival compared with standard chemotherapy. This is not a cure, but for many women with triple-negative breast cancer it offers some vitally important extra months with their loved ones.”

Approximately 8,000 people are diagnosed with TNBC each year, around a third of whom will experience a metastatic recurrence of their disease within a median period of 2.6 years.

The NICE recommendation was based on data from the Phase III ASCENT study of sacituzumab govitecan. The study reported significantly and clinically meaningful improvements in its primary efficacy endpoint of progression-free survival, when compared to treatment with chemotherapy.

The treatment was made available by the SMC for use on the NHS in Scotland in March 2022, and Wales will now implement NICE guidance.

Dr Véronique Walsh, Vice President and General Manager, UK & Ireland said: “The availability of this important treatment option for people with triple-negative breast cancer has been a key priority of ours for many months and we are delighted that Trodelvy will be routinely available to eligible patients on the NHS in England and Wales. We are grateful for the efforts of the entire breast cancer community that stressed the urgency of this decision and supported the process.”

Ana Ovey

Related Content

No items found

Latest content